Franklin Genomic Advancement Fund (HELX)

Overview

The fund is a specialized investment vehicle focusing on the burgeoning field of genomic advancements. It dedicates at least 80% of its net assets to equity securities of companies actively engaged in the development and application of genomic and biotechnological innovations. Although its investment portfolio can span various economic sectors, the fund primarily targets companies within the healthcare industry. This focus reflects a strategic commitment to sectors anticipated to experience significant growth due to advancements in genomics. The fund is characterized as non-diversified, implying a concentrated investment strategy that may focus on a smaller number of companies within its thematic scope of genomic developments.

Products and Services

• Equity Securities of Genomic Companies

This includes investments in common stocks of companies that are at the forefront of genomic research and biotechnology. These are firms involved in the discovery, development, and commercialization of genomic sequences and their applications in medicine, agriculture, and other fields. The fund targets companies with a strong potential for growth, driven by innovation and advancements in genomics.

• Healthcare Industry Concentration

Given the intrinsic link between genomics and healthcare, the fund places a significant emphasis on investing in companies within the healthcare sector. This includes biotech firms developing therapeutic drugs, diagnostic companies focusing on genomic-based tests, and businesses involved in personalized medicine. The strategy aims to harness the sector's growth potential driven by technological advancements in genomics and its applications in healthcare.